In the wake of the increase in Current Liabilities in the fourth quarter 2025, Quick Ratio fell to 7.29 below Day One Biopharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 103 other companies have achieved higher Quick Ratio than Day One Biopharmaceuticals Inc in fourth quarter 2025. While Quick Ratio total ranking has improved so far during the Q4 2025 to 328, from total ranking in the third quarter 2025 at 353.

Explain Quick Ratio?
How much Cash & cash equivalents DAWN�s has?
What are DAWN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/DAWN/financial-strength

https://api.csimarket.com/api/v1/companies/DAWN/fundamentals

https://api.csimarket.com/api/v1/companies/DAWN/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

DAWN Quick Ratio	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2	(Mar 31 2025) Q1	(Dec 31 2024) Q4
Y / Y Current Liabilities Change	-24.24 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-17.04 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	7.29	Subscribe	Subscribe	Subscribe	Subscribe
DAWN's Total Ranking	# 328	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	7.18 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-2.32 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 104
Healthcare Sector	# 158
Overall Market	# 328

Quick Ratio Statistics
High	Average	Low
66.49	20.23	3.87
(Jun 30 2021)		(Jun 30 2024)

Financial Statements
Day One Biopharmaceuticals Inc 's Current Liabilities	$ 61 Millions	Visit DAWN's Balance sheet
Day One Biopharmaceuticals Inc 's Cash & cash equivalent	$ 441 Millions	Visit DAWN's Balance sheet
Source of DAWN's Sales		Visit DAWN's Sales by Geography

Cumulative Day One Biopharmaceuticals Inc 's Quick Ratio

DAWN's Quick Ratio for the trailling 12 Months

DAWN Quick Ratio	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	-10.96 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	2.76 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	8.42	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 1128	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-8.23 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-4.75 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to DAWN Financial Strength Comparisons >> Go to Compare DAWN Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Day One Biopharmaceuticals Inc 's average Cash & cash equivalent, this led to increase in in Day One Biopharmaceuticals Inc 's Quick Ratio to 8.42, Quick Ratio remained below DAWN average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 483 other companies have achieved higher Quick Ratio than Day One Biopharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 2642 to 4524.

Explain Quick Ratio?
How much Cash & cash equivalents DAWN�s has?
What are DAWN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 484
Healthcare Sector	# 989
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
43.78	12.87	1.04
(Dec 31 2021)		(Sep 30 2025)

Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Dec 31 2025 MRQ Cash & cash equivalent	Dec 31 2025 MRQ Current Liabilities
Siga Technologies Inc	19.99	$ 154.966 Millions	$ 7.753 Millions
Trevi Therapeutics Inc	19.94	$ 188.260 Millions	$ 9.442 Millions
Edgewise Therapeutics inc	19.37	$ 530.109 Millions	$ 27.370 Millions
Maplight Therapeutics Inc	18.80	$ 305.103 Millions	$ 16.229 Millions
Braveheart Bio, Inc.	17.01	$ 89.161 Millions	$ 5.242 Millions
Kezar Life Sciences Inc	16.92	$ 71.878 Millions	$ 4.248 Millions
Stoke Therapeutics Inc	16.90	$ 284.670 Millions	$ 16.840 Millions
Design Therapeutics Inc	16.84	$ 219.845 Millions	$ 13.055 Millions
Neurogene Inc	16.39	$ 269.013 Millions	$ 16.411 Millions
Edesa Biotech Inc	16.00	$ 12.100 Millions	$ 0.756 Millions
Xbiotech Inc	15.83	$ 125.551 Millions	$ 7.929 Millions
Tango Therapeutics Inc	15.83	$ 343.138 Millions	$ 21.679 Millions
Mira Pharmaceuticals Inc	15.71	$ 11.030 Millions	$ 0.702 Millions
Phio Pharmaceuticals Corp	15.69	$ 21.031 Millions	$ 1.340 Millions
Alto Neuroscience Inc	15.58	$ 176.484 Millions	$ 11.325 Millions
Veradermics Inc	15.50	$ 141.862 Millions	$ 9.152 Millions
Ocular Therapeutix Inc	15.36	$ 737.060 Millions	$ 47.989 Millions
Nuvalent Inc	15.05	$ 1,371.952 Millions	$ 91.171 Millions
Bioharvest Sciences Inc	14.57	$ 46.050 Millions	$ 3.160 Millions
Immunome Inc	14.55	$ 654.782 Millions	$ 44.990 Millions
Cryoport inc	14.54	$ 413.300 Millions	$ 28.426 Millions
Eupraxia Pharmaceuticals Inc	14.51	$ 80.563 Millions	$ 5.551 Millions
Climb Bio Inc	14.47	$ 101.080 Millions	$ 6.984 Millions
Synlogic Inc	14.41	$ 14.668 Millions	$ 1.018 Millions
Cervomed Inc	14.35	$ 20.864 Millions	$ 1.454 Millions
Bicara Therapeutics Inc	14.33	$ 414.801 Millions	$ 28.949 Millions
Tyra Biosciences Inc	14.15	$ 256.003 Millions	$ 18.094 Millions
Cogent Biosciences Inc	14.08	$ 900.765 Millions	$ 63.953 Millions
Keros Therapeutics Inc	14.08	$ 287.415 Millions	$ 20.414 Millions
Amylyx Pharmaceuticals Inc	13.97	$ 316.979 Millions	$ 22.688 Millions

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.